

Korea's Samsung Biologics invests over KRW 1.9 T in new facility

17 March 2023 | News

Announces construction of Plant 5 to commence Bio Campus II capacity expansion



Samsung Biologics, a leading contract development and manufacturing organisation (CDMO) based in South Korea, has announced that the company will commence the construction of a fifth plant as part of its strategic expansion in response to increased market demand.

The company will invest over KRW 1.9 trillion in the new facility and break ground in the first half of this year with the aim to commence operations in 2025.

Located near its current Songdo site, Plant 5 will be the first facility of the company's second Bio Campus, encompassing an area of 96,000m² and holding a capacity of 180,000 liters. Upon Plant 5's full completion, Samsung Biologics will maintain its global biomanufacturing capacity leadership with a total of 784,000 liters.

The plant is expected to further maximise operational efficiency, allowing the company to leverage existing capabilities, expertise and technologies acquired through its experience with Plants 1 through 4, while introducing advanced digitalisation and sustainability features.

Samsung Biologics purchased 360,000m² of land in July 2022 for its second Bio Campus, which will house additional large-scale plants and an open innovation center. The company will be investing KRW 7.5 trillion in its second Bio Campus.

The company's existing Plants 1 through 3 are under near-full utilisation and its Plant 4, which started partial operations in October last year, is expected to commence full operations by midyear.

Samsung Biologics will also enhance its presence in the US with the opening of a regional office in New Jersey.